- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about RHHBY
Recent news which mentions RHHBY
These OTC Securities Reported The Most Trading Volume In January – With Possible Sustained Interest In International Operators
February 14, 2022
From Benzinga
Why Are Seagen Shares Sinking Today?
February 10, 2022
From Benzinga
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
February 06, 2022
From Benzinga
From Benzinga
The Daily Biotech Pulse: Big Pharma Earnings Prove Lackluster, Mersana Inks $1B ADC R&D Deal, Syros Gets Orphan Drug Designation
February 03, 2022
From Benzinga
From Benzinga
Novartis Expects FY22 Sales, Profit Growth; Sandoz Review Continues
February 02, 2022
From Benzinga
Biogen Exercises Option To Participate Developing Genentech's Bispecific Antibody, Mosunetuzumab
February 01, 2022
From Benzinga
The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News
January 31, 2022
From Benzinga
FDA Approves First Injectable Eye Medicine For Vision Loss Disorder - Genentech's Vabysmo
January 31, 2022
From Benzinga
Genentech's Evrysdi Application Under FDA Priority Review For Use In Babies Below 2 Months
January 25, 2022
From Benzinga
These OTC Securities Had the Most Trading Activity in December
January 25, 2022
From Benzinga
3 Clinical Trials to Watch in the First Half of 2022
January 22, 2022
From Motley Fool
2 Risky Growth Stocks That Could Make You Filthy Rich
January 16, 2022
From Motley Fool
Where Will Biogen Be in 5 Years?
January 15, 2022
From Motley Fool
Medicare pulls back on coverage of an Alzheimer’s drug
January 12, 2022
From MarketWatch
From Benzinga
Why Shares of ImmunoGen Jumped 20.3% in December
January 03, 2022
From Motley Fool
Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates
December 31, 2021
From Benzinga
Why Lineage Cell Therapeutics Zoomed Higher Today
December 20, 2021
From Motley Fool
Lineage, Genentech Ink Cell Therapy Licensing Pact For Ocular Diseases
December 20, 2021
From Benzinga
These OTC Securities Had the Most Trading Activity in November
December 16, 2021
From Benzinga
The Daily Biotech Pulse: Calliditas Snags FDA Nod, Novartis to Buy Back $15B In Shares, Valneva Touts Vaccine Data, Immix, Bionomics Debut On Wall Street
December 16, 2021
From Benzinga
Novartis Launches New Share Buyback Program Of Up To $15B
December 16, 2021
From Benzinga
After Roche Walks Away, Atea Puts Break On Late-Stage COVID-19 Oral Antiviral Trial
December 15, 2021
From Benzinga
Roche's Polivy Combo Boosts Survival In Early-Stage Lymphoma Patients
December 14, 2021
From Benzinga
The Daily Biotech Pulse: Mesoblast, Novartis Sever COVID-19 Treatment Partnerships, Sigilon To Reduce Workforce, ASH Presentations Move Stocks
December 14, 2021
From Benzinga
Roche Uncorks Favorable Responses From Mosunetuzumab In Follicular Lymphoma Settings
December 13, 2021
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.